228 related articles for article (PubMed ID: 20332054)
1. Unmasking the complexities of mucinous ovarian carcinoma.
Frumovitz M; Schmeler KM; Malpica A; Sood AK; Gershenson DM
Gynecol Oncol; 2010 Jun; 117(3):491-6. PubMed ID: 20332054
[TBL] [Abstract][Full Text] [Related]
2. Mucinous tumors of the ovary: current thoughts on diagnosis and management.
Brown J; Frumovitz M
Curr Oncol Rep; 2014 Jun; 16(6):389. PubMed ID: 24777667
[TBL] [Abstract][Full Text] [Related]
3. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
5. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
6. Mucinous epithelial ovarian carcinoma.
Perren TJ
Ann Oncol; 2016 Apr; 27 Suppl 1():i53-i57. PubMed ID: 27141073
[TBL] [Abstract][Full Text] [Related]
7. Mucinous ovarian cancer.
Harrison ML; Jameson C; Gore ME
Int J Gynecol Cancer; 2008; 18(2):209-14. PubMed ID: 17624989
[TBL] [Abstract][Full Text] [Related]
8. Alteration of BRCA-1 tumor suppressor gene expression in serous and mucinous ovarian neoplasms in the benign-borderline-malignant pathway.
Yousif HMA; Mohammed RAA
Curr Probl Cancer; 2019 Aug; 43(4):377-385. PubMed ID: 30446260
[TBL] [Abstract][Full Text] [Related]
9. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
Werness BA; DiCioccio RA; Piver MS
Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
[TBL] [Abstract][Full Text] [Related]
10. Recent Insights into Mucinous Ovarian Carcinoma.
Ricci F; Affatato R; Carrassa L; Damia G
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29795040
[TBL] [Abstract][Full Text] [Related]
11. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
12. Early stage mucinous ovarian cancer: A review.
Crane EK; Brown J
Gynecol Oncol; 2018 Jun; 149(3):598-604. PubMed ID: 29429591
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
Jordan SJ; Green AC; Whiteman DC; Webb PM;
Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
[TBL] [Abstract][Full Text] [Related]
14. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.
Ledermann JA; Luvero D; Shafer A; O'Connor D; Mangili G; Friedlander M; Pfisterer J; Mirza MR; Kim JW; Alexandre J; Oza A; Brown J
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S14-9. PubMed ID: 25341574
[TBL] [Abstract][Full Text] [Related]
16. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
17. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
18. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
19. Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.
Ye F; Hu Y; Zhou C; Hu Y; Chen H
Pathobiology; 2012; 79(6):307-13. PubMed ID: 22688257
[TBL] [Abstract][Full Text] [Related]
20. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]